GlaxoSmithKline Pharmaceuticals Limited (IN:GLAXO)
:GLAXO
Want to see IN:GLAXO full AI Analyst Report?
Top Page
GlaxoSmithKline Pharmaceuticals Limited
(GLAXO)
Select Model
Select Model
Rating:69Neutral
Price Target:
₹2,647.00
▲(6.59% Upside)
Action:Reiterated
Date:05/15/26
The score is led by strong financial performance—improving margins, high ROE, and minimal leverage—partly offset by a neutral-to-weak technical backdrop (below longer-term moving averages) and a relatively expensive valuation (high P/E despite a moderate dividend yield).
Positive Factors
Strong Profitability
High 2026 net (~27%) and EBIT (~33%) margins indicate durable pricing power and operating leverage in its branded formulation model. Sustained margins increase free cash generation, support reinvestment in R&D/brands and provide a structural buffer versus lower‑margin competitors.
Negative Factors
Profitability Volatility
Large swings in margins — including a >50% outlier in 2022 — suggest one-offs or timing effects materially influence reported profits. This volatility weakens earnings predictability, complicates long-term planning for R&D and commercial investment, and raises forecasting risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Profitability
High 2026 net (~27%) and EBIT (~33%) margins indicate durable pricing power and operating leverage in its branded formulation model. Sustained margins increase free cash generation, support reinvestment in R&D/brands and provide a structural buffer versus lower‑margin competitors.
Read all positive factors
GlaxoSmithKline Pharmaceuticals Limited (GLAXO) vs. iShares MSCI India ETF (INDA)
Market Cap
₹397.70B
Dividend Yield2.16%
Average Volume (3M)1.83K
Price to Earnings (P/E)37.3
Beta (1Y)0.58
Revenue Growth1.93%
EPS Growth11.68%
CountryIN
Employees3,211
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)56.39
Shares Outstanding169,406,040
10 Day Avg. Volume1,472
30 Day Avg. Volume1,831
Financial Highlights & Ratios
PEG Ratio3.20
Price to Book (P/B)17.06
Price to Sales (P/S)10.12
P/FCF Ratio39.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)69.53
Revenue Forecast (FY)₹42.07B
GlaxoSmithKline Pharmaceuticals Limited Business Overview & Revenue Model
Company Description
GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally. The company offers prescription and non-prescription drugs for anti-in...
How the Company Makes Money
GLAXO primarily makes money by selling pharmaceutical and healthcare products in India through a branded, formulation-led model. Revenue is mainly generated from: (1) Domestic sales of branded prescription medicines: The company markets finished-d...
GlaxoSmithKline Pharmaceuticals Limited Financial Statement Overview
Summary
Income Statement
82
Very Positive
Balance Sheet
92
Very Positive
Cash Flow
78
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 36.86B | 38.22B | 37.26B | 34.42B | 32.26B | 32.64B |
| Gross Profit | 20.94B | 17.97B | 22.53B | 20.22B | 18.68B | 18.14B |
| EBITDA | 13.68B | 13.09B | 13.28B | 8.88B | 9.04B | 8.49B |
| Net Income | 9.55B | 10.36B | 9.28B | 5.90B | 6.11B | 16.95B |
Balance Sheet | ||||||
| Total Assets | 36.65B | 43.24B | 41.08B | 35.57B | 33.27B | 46.33B |
| Cash, Cash Equivalents and Short-Term Investments | 20.61B | 27.82B | 24.98B | 18.57B | 16.54B | 29.03B |
| Total Debt | 357.10M | 332.70M | 99.50M | 186.65M | 155.40M | 200.76M |
| Total Liabilities | 19.57B | 20.56B | 21.57B | 17.79B | 15.85B | 19.70B |
| Stockholders Equity | 17.08B | 22.67B | 19.51B | 17.78B | 17.41B | 26.63B |
Cash Flow | ||||||
| Free Cash Flow | 1.67B | 9.67B | 12.67B | 5.51B | 4.40B | 7.76B |
| Operating Cash Flow | 1.84B | 10.22B | 12.90B | 5.82B | 4.84B | 8.11B |
| Investing Cash Flow | 3.40B | 2.78B | -458.10M | 87.12M | 8.08B | -4.06B |
| Financing Cash Flow | -7.23B | -7.37B | -7.69B | -5.61B | -15.43B | -5.24B |
GlaxoSmithKline Pharmaceuticals Limited Technical Analysis
Negative
2483.35
Price Trends
2404.67
Negative
2441.63
Negative
2571.21
Negative
Market Momentum
-5.43
Positive
41.40
Neutral
9.34
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:GLAXO, the sentiment is Negative. The current price of 2483.35 is above the 20-day moving average (MA) of 2418.25, above the 50-day MA of 2404.67, and below the 200-day MA of 2571.21, indicating a bearish trend. The MACD of -5.43 indicates Positive momentum. The RSI at 41.40 is Neutral, neither overbought nor oversold. The STOCH value of 9.34 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:GLAXO.
GlaxoSmithKline Pharmaceuticals Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ₹1.04T | 19.82 | ― | 0.57% | 23.12% | 62.27% | |
71 Outperform | ₹4.51T | 30.62 | ― | 0.91% | 10.09% | -4.53% | |
69 Neutral | ₹397.70B | 37.33 | ― | 2.16% | 1.93% | 11.68% | |
69 Neutral | ₹1.13T | 25.49 | ― | 0.87% | 2.23% | -26.44% | |
67 Neutral | ₹1.10T | 24.38 | ― | 0.63% | 3.19% | -24.26% | |
66 Neutral | ₹1.50T | 51.30 | ― | 0.84% | 12.74% | 22.02% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:GLAXO
GlaxoSmithKline Pharmaceuticals Limited
2,347.60
-632.17
-21.22%
IN:CIPLA
Cipla Ltd
1,399.50
-52.28
-3.60%
IN:DRREDDY
Dr. Reddy's Laboratories Ltd.
1,321.90
106.96
8.80%
IN:LUPIN
Lupin Limited
2,283.40
327.10
16.72%
IN:SUNPHARMA
Sun Pharmaceutical Industries Limited
1,880.50
177.21
10.40%
IN:TORNTPHARM
Torrent Pharmaceuticals Ltd
4,429.85
1,244.77
39.08%
GlaxoSmithKline Pharmaceuticals Limited Corporate Events
GSK Pharma India Shareholders Approve Appointment of CFO Ronojit Biswas via Postal Ballot
Apr 8, 2026
GlaxoSmithKline Pharmaceuticals Limited has concluded a postal ballot process conducted via remote e-voting to seek shareholder approval for key board and management changes. The process, held in compliance with the Companies Act and SEBI listing ...
GSK Pharma India Publishes Postal Ballot Notice Advertisements in Line With LODR Norms
Mar 11, 2026
GlaxoSmithKline Pharmaceuticals Limited has notified the stock exchanges that it has published newspaper advertisements regarding a postal ballot notice, in compliance with Regulation 47 of the Listing Obligations and Disclosure Requirements Regul...
GSK Pharma India Seeks Shareholder Nod on CFO Appointment via E‑Voting
Mar 7, 2026
GlaxoSmithKline Pharmaceuticals Limited has initiated a postal ballot process to seek shareholder approval for the appointment and remuneration of Mr. Ronojit Biswas as Whole-time Director and Chief Financial Officer. The move, conducted entirely ...
GSK Pharma India Seeks Shareholder Nod for CFO Appointment via E-Voting Postal Ballot
Mar 7, 2026
GlaxoSmithKline Pharmaceuticals Limited has initiated a shareholder approval process via an electronic postal ballot to confirm the appointment and remuneration of Mr. Ronojit Biswas as Whole-time Director and Chief Financial Officer. The move und...
GSK Pharma India Names Ronojit Biswas as New CFO Amid Leadership Transition
Mar 2, 2026
GlaxoSmithKline Pharmaceuticals Limited has announced that its board has approved the appointment of Ronojit Biswas as Whole-Time Director and Chief Financial Officer for a three-year term starting April 1, 2026. Biswas, a veteran GSK finance exec...
GSK Pharma India Names Ronojit Biswas CFO as Juby Chandy Moves to APAC Role
Mar 2, 2026
GlaxoSmithKline Pharmaceuticals Limited has announced a leadership change in its finance function, appointing Ronojit Biswas as Whole-Time Director and Chief Financial Officer for a three-year term starting 1 April 2026. Biswas, a long-serving GSK...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.